Receptor for advanced glycation end-products in neurodegenerative diseases

Reviews in the Neurosciences

Volumn 26, Issue 6, 2015, Pages 691-698

  Juranek, Judyta ^a,b   Ray, Rashmi ^c   Banach, Marta ^d   Rai, Vivek ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^c INSTITUTE OF LIFE SCIENCES   (India)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

neurodegeneration; neurodegenerative disorders; receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; FAMILIAL AMYLOID POLYNEUROPATHY; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MOTONEURON; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVIEW; TISSUE DEGENERATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84948746896     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2015-0003     Document Type: Review

References (61)

1. Anzilotti, S., Giampa, C., Laurenti, D., Perrone, L., Bernardi, G., Melone, M.A., and Fusco, F.R. (2012). Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Res. Bull. 87, 350-358
2. Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P.M., Chen, J., Hong, M., Luther, T., Henle, T., Kloting, I., et al. (2001). Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50, 2792-2808
3. Bekircan-Kurt, C.E., Uceyler, N., and Sommer, C. (2014). Cutaneous activation of RAGE in nonsystemic vasculitic and diabetic neuropathy. Muscle Nerve 50, 377-383
4. Braak, H., Del, T.K., Rub, U., de Vos, R.A., Jansen, S.E.N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211
5. Casula, M., Iyer, A.M., Spliet, W.G., Anink, J.J., Steentjes, K., Sta, M., Troost, D., and Aronica, E. (2011). Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179, 233-243
6. Cho, H.J., Son, S.M., Jin, S.M., Hong, H.S., Shin, D.H., Kim, S.J., Huh, K., and Mook-Jung, I. (2009). RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 23, 2639-2649
7. Chou, S.M., Wang, H.S., Taniguchi, A., and Bucala, R. (1998). Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol. Med. 4, 324-332
8. da Costa, G., Gomes, R.A., Guerreiro, A., Mateus, E., Monteiro, E., Barroso, E., Coelho, A.V., Freire, A.P., and Cordeiro, C. (2011). Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activity. PLoS One 6, e24850
9. Dalfo, E., Portero-Otin, M., Ayala, V., Martinez, A., Pamplona, R., and Ferrer, I. (2005). Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64, 816-830
10. Ding, Q. and Keller, J.N. (2005). Evaluation of RAGE isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 1746, 18-27
11. Donato, R. (2001). S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell. Biol. 33, 637-668
12. Franciosi, S., Shim, Y., Lau, M., Hayden, M.R., and Leavitt, B.R. (2013). A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord. 28, 1987-1994
13. Freixes, M., Rodriguez, A., Dalfo, E., and Ferrer, I. (2006). Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol. Aging 27, 1807-1815
14. Gao, J., Teng, J., Liu, H., Han, X., Chen, B., and Xie, A. (2014). Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population. Neurosci. Lett. 559, 158-162
15. Haslbeck, K.M., Neundorfer, B., Schlotzer-Schrehardtt, U., Bierhaus, A., Schleicher, E., Pauli, E., Haslbeck, M., Hecht, M., Nawroth, P., and Heuss, D. (2007). Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol. Res. 29, 103-110
16. Hofmann, M.A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901
17. Hughes, R.A. (2002). Peripheral neuropathy. Br. Med. J. 324, 466-469
18. Huttunen, H.J., Kuja-Panula, J., Sorci, G., Agneletti, A.L., Donato, R., and Rauvala, H. (2000). Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J. Biol. Chem. 275, 40096-40105
19. Huttunen, H.J., Kuja-Panula, J., and Rauvala, H. (2002). Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J. Biol. Chem. 277, 38635-38646
20. Ilzecka, J. (2009). Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 120, 119-122
21. Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376
22. Juranek, J.K., Aleshin, A., Rattigan, E.M., Johnson, L., Qu, W., Song, F., Ananthakrishnan, R., Quadri, N., Yan, S.D., Ramasamy, R., et al. (2010). Morphological changes and immunohistochemical expression of RAGE and its ligands in the sciatic nerve of hyperglycemic pig (Sus scrofa). Biochem. Insights 2010, 47-59
23. Juranek, J.K., Geddis, M.S., Song, F., Zhang, J., Garcia, J., Rosario, R., Yan, S.F., Brannagan, T.H., and Schmidt, A.M. (2013a). RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 62, 931-943
24. Juranek, J.K., Kothary, P., Mehra, A., Hays, A., Brannagan, T.H. 3rd, and Schmidt, A.M. (2013b). Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies. Brain Behav. 3, 701-709
25. Kim, S.W., Lim, C.M., Kim, J.B., Shin, J.H., Lee, S., Lee, M., and Lee, J.K. (2011). Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotoxicol. Res. 20, 159-169
26. Lee, D., Park, C.W., Paik, S.R., and Choi, K.Y. (2009). The modification of á-synuclein by dicarbonyl compounds inhibits its fibrilforming process. Biochim. Biophys. Acta 1794, 421-430
27. Lee, J.J., Wang, P.W., Yang, I.H., Wu, C.L., and Chuang, J.H. (2015). Amyloid-β mediates the receptor of advanced glycation end product-induced pro-inflammatory response via Toll-like receptor 4 signaling pathway in retinal ganglion cell line RGC-5. Int. J. Biochem. Cell. Biol. 64, 1-10
28. Li, J. and Schmidt, A.M. (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272, 16498-16506
29. Liu, R., Wu, C.X., Zhou, D., Yang, F., Tian, S., Zhang, L., Zhang, T.T., and Du, G.H. (2012). Pinocembrin protects against β-amyloidinduced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC Med. 10, 105
30. Lue, L.-F., Walker, D.G., Brachova, L., Beach, T.G., Rogers, J., Schmidt, A.M., Stern, D.M., and Yan, S.D. (2001). Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171, 29-45
31. Ma, L. and Nicholson, L.F. (2004). Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res. 1018, 10-17
32. Mackic, J.B., Stins, M., McComb, J.G., Calero, M., Ghiso, J., Kim, K.S., Yan, S..D, Stern, D., Schmidt, A.M., Frangione, B., et al. (1998). Human blood-brain barrier receptors for Alzheimer's amyloid-β40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102, 734-743
33. Matrone, C., Djelloul, M., Taglialatela, G., and Perrone, L. (2015). Inflammatory risk factors and pathologies promoting Alzheimer's disease progression: is RAGE the key? Histol. Histopathol. 30, 125-139
34. Matsunaga, N., Anan, I., Forsgren, S., Nagai, R., Rosenberg, P., Horiuchi, S., Ando, Y., and Suhr, O.B. (2002). Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-κB activation. Acta Neuropathol. 104, 441-447
35. Mattson, M.P. and Camandola, S. (2001). NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107, 247-254
36. Neeper, M., Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C., Elliston, K., Stern, D., and Shaw, A. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004
37. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., et al. (2007). Sirtuin 2 inhibitors rescue á-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519
38. Padmaraju, V., Bhaskar, J.J., Prasada, R.U.J., Salimath, P.V., and Rao, K.S. (2011). Role of advanced glycation on aggregation and DNA binding properties of á-synuclein. J. Alzheimers Dis. 24, 211-221
39. Park, S.Y., Kim, Y.A., Hong, Y.H., Moon, M.K., Koo, B.K., and Kim, T.W. (2014). Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy. J. Clin. Neurol. 10, 334-341
40. Piras, S., Furfaro, A.L., Piccini, A., Passalacqua, M., Borghi, R., Carminati, E., Parodi, A., Colombo, L., Salmona, M., Pronzato, M.A., et al. (2014). Monomeric Aβ1-42 and RAGE: key players in neuronal differentiation. Neurobiol. Aging 35, 1301-1308
41. Ramasamy, R., Vannucci, S.J., Yan, S.S., Herold, K., Yan, S.F., and Schmidt, A.M. (2005). Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16R-28R
42. Rong, L.L., Gooch, C., Szabolcs, M., Herold, K.C., Lalla, E., Hays, A.P., Yan, S.F., Yan, S.S., and Schmidt, A.M. (2005). RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor. Neurol. Neurosci. 23, 355-365
43. Sabbagh, M.N., Agro, A., Bell, J., Aisen, P.S., Schweizer, E., and Galasko, D. (2011). PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 25, 206-212
44. Sajithlal, G., Huttunen, H., Rauvala, H., and Munch, G. (2002). Receptor for advanced glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma cells. J. Biol. Chem. 277, 6888-6897
45. Saleh, A., Smith, D.R., Tessler, L., Mateo, A.R., Martens, C., Schartner, E., Van der Ploeg, R., Toth, C., Zochodne, D.W., and Fernyhough, P. (2013). Receptor for advanced glycation end-products (RAGE) activates divergent signaling pathways to augment neurite outgrowth of adult sensory neurons. Exp. Neurol. 249, 149-159
46. Saraiva, M.J., Birken, S., Costa, P.P., and Goodman, D.S. (1984). Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Ann. NY Acad. Sci. 435, 86-100
47. Sasaki, N., Takeuchi, M., Chowei, H., Kikuchi, S., Hayashi, Y., Nakano, N., Ikeda, H., Yamagishi, S., Kitamoto, T., Saito, T., et al. (2002). Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 326, 117-120
48. Sathe, K., Maetzler, W., Lang, J.D., Mounsey, R.B., Fleckenstein, C., Martin, H.L., Schulte, C., Mustafa, S., Synofzik, M., Vukovic, Z., et al. (2012). S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 135, 3336-3347
49. Sbai, O., Devi, T.S., Melone, M.A., Feron, F., Khrestchatisky, M., Singh, L.P., and Perrone, L. (2010). RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. J. Cell. Sci. 123, 4332-4339
50. Schmidt, A.M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267, 14987-14997
51. Shibata, N., Hirano, A., Hedley-Whyte, E.T., Dal Canto, M.C., Nagai, R., Uchida, K., Horiuchi, S., Kawaguchi, M., Yamamoto, T., and Kobayashi, M. (2002). Selective formation of certain advanced glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation. Acta Neuropathol. 104, 171-178
52. Shorter, J. and Lindquist, S. (2005). Prions as adaptive conduits of memory and inheritance. Nat. Rev. Genet. 6, 435-450
53. Sousa, M.M., Yan, S.D., Stern, D., and Saraiva, M.J. (2000). Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κB (NF-κB) activation. Lab. Invest. 80, 1101-1110
54. Taguchi, A., Blood, D.C., del Toro, G., Canet, A., Lee, D.C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000). Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354-360
55. Takamiya, R., Takahashi, M., Myint, T., Park, Y.S., Miyazawa, N., Endo, T., Fujiwara, N., Sakiyama, H., Misonou, Y., Miyamoto, Y., et al. (2003). Glycation proceeds faster in mutated Cu, Zn- superoxide dismutases related to familial amyotrophic lateral sclerosis. FASEB J. 17, 938-940
56. Teismann, P., Sathe, K., Bierhaus, A., Leng, L., Martin, H.L., Bucala, R., Weigle, B., Nawroth, P.P., and Schulz, J.B. (2012). Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging 33, 2478-2490
57. Toth, C., Rong, L.L., Yang, C., Martinez, J., Song, F., Ramji, N., Brussee, V., Liu, W., Durand, J., Nguyen, M.D., et al. (2008). Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 57, 1002-1017
58. Wang, L., Li, S., and Jungalwala, F.B. (2008). Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J. Neurosci. Res. 86, 1254-1266
59. Xu, Y., Toure, F., Qu, W., Lin, L., Song, F., Shen, X., Rosario, R., Garcia, J., Schmidt, A.M., and Yan, S.F. (2010). Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285, 23233-23240
60. Yan, S.D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691
61. Yan, S.D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A.M., Stern, D., et al. (2000). Receptordependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643-651